## The following content was supplied by the authors as supporting material and has not been copy-edited or verified by JBJS.

Supplementary data 1. Box plots of eight natural log-transformed synovial biomarkers concentrations in PJI group compared to the control group. The biomarkers for these additional analyses were chosen based on Figure 1.

Supplementary data 2. Box plots of seven natural log-transformed serum biomarkers concentrations in PJI group compared to the control group. The biomarkers for these additional analyses were chosen based on Figure 1.

Supplemental data 3. Area Under Curve (AUC) and P-values for biomarkers reaching 0.05 significance.

	AUC (95% CI)	Optimal specificity and sensitivity	P (Control vs PJI)
Synovial fluid			
IL-10	0.84 (0.69-1.00)	1.00, 0.67	0.0061
TSLP	0.83 (0.66-0.99)	1.00, 0.67	0.0095
IL-22	0.78 (0.59-0.97)	1.00, 0.67	0.025
IL-19	0.77 (0.59-0.96)	0.89, 0.60	0.029
IL-20	0.76 (0.57-0.96)	1.00, 0.60	0.037
IL-35	0.76 (0.57-0.95)	1.00, 0.53	0.040
APRIL	0.76 (0.54-0.97)	1.00, 0.73	0.043
MMP-3	0.75 (0.55-0.95)	1.00, 0.60	0.049
Serum			
sTNF-R2	0.85 (0.69-1.00)	0.70, 0.87	0.0043
BAFF	0.81 (0.64-0.99)	0.90, 0.73	0.0099
MMP-2	0.80 (0.62-0.98)	0.60, 0.93	0.014
sIL-6Ra	0.79 (0.60-0.97)	0.80, 0.73	0.018
APRIL	0.78 (0.60-0.97)	0.90, 0.60	0.020
TSLP	0.75 (0.54-0.96)	0.60, 0.87	0.040
Pentraxin-3	0.75 (0.55-0.94)	0.90, 0.60	0.043

Supplementary data 3. Area Under Curve (AUC) and P-values for biomarkers reaching 0.05 significance.

Supplementary data 4. Receiving operating characteristic curves (ROC) for eight additional synovial biomarkers.

Page 5

Supplementary data 5. Receiving operating characteristic curves (ROC) for seven additional serum biomarkers.